FY2027 EPS Estimates for Immunocore Boosted by HC Wainwright

Immunocore Holdings plc (NASDAQ:IMCR - Free Report) - Analysts at HC Wainwright increased their FY2027 EPS estimates for Immunocore in a research report issued to clients and investors on Friday, February 28th. HC Wainwright analyst P. Trucchio now forecasts that the company will post earnings per share of $1.10 for the year, up from their prior estimate of $1.04. HC Wainwright has a "Buy" rating and a $100.00 price objective on the stock. The consensus estimate for Immunocore's current full-year earnings is ($0.94) per share. HC Wainwright also issued estimates for Immunocore's FY2028 earnings at $4.46 EPS and FY2029 earnings at $7.96 EPS.

Several other equities analysts have also issued reports on IMCR. Mizuho lowered Immunocore from an "outperform" rating to a "neutral" rating and decreased their target price for the stock from $72.00 to $38.00 in a research report on Monday, November 11th. Morgan Stanley reissued an "equal weight" rating and set a $35.00 price objective (down previously from $74.00) on shares of Immunocore in a research note on Friday, December 13th. Finally, Needham & Company LLC reaffirmed a "buy" rating and issued a $71.00 target price on shares of Immunocore in a research note on Thursday, February 27th. One analyst has rated the stock with a sell rating, four have given a hold rating and eight have assigned a buy rating to the company's stock. According to data from MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and an average target price of $65.64.

Remove Ads

Immunocore Trading Up 0.1 %

Shares of Immunocore stock traded up $0.04 during trading on Monday, reaching $30.29. 117,956 shares of the company were exchanged, compared to its average volume of 224,428. The business has a 50-day moving average price of $30.14 and a 200-day moving average price of $31.70. The firm has a market capitalization of $1.52 billion, a price-to-earnings ratio of -31.85 and a beta of 0.79. The company has a quick ratio of 3.76, a current ratio of 3.78 and a debt-to-equity ratio of 1.03. Immunocore has a twelve month low of $27.69 and a twelve month high of $66.00.

Hedge Funds Weigh In On Immunocore

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Geode Capital Management LLC lifted its holdings in shares of Immunocore by 1.2% in the fourth quarter. Geode Capital Management LLC now owns 35,492 shares of the company's stock valued at $1,047,000 after purchasing an additional 420 shares in the last quarter. GF Fund Management CO. LTD. acquired a new position in Immunocore during the fourth quarter valued at approximately $25,000. China Universal Asset Management Co. Ltd. lifted its stake in Immunocore by 12.9% in the fourth quarter. China Universal Asset Management Co. Ltd. now owns 8,393 shares of the company's stock valued at $248,000 after acquiring an additional 960 shares during the last quarter. NEOS Investment Management LLC raised its stake in Immunocore by 10.9% in the fourth quarter. NEOS Investment Management LLC now owns 11,194 shares of the company's stock valued at $330,000 after buying an additional 1,102 shares during the period. Finally, Pier Capital LLC increased its holdings in shares of Immunocore by 1.4% in the third quarter. Pier Capital LLC now owns 82,480 shares of the company's stock valued at $2,568,000 after purchasing an additional 1,174 shares during the last quarter. 84.50% of the stock is owned by institutional investors and hedge funds.

About Immunocore

Immunocore Holdings plc, a commercial-stage biotechnology company, engages in the development of immunotherapies for the treatment of cancer, infectious, and autoimmune diseases. The company offers KIMMTRAK for the treatment of patients with unresectable or metastatic uveal melanoma. It also develops other programs for oncology, including tebentafusp that is in Phase 2/3 clinical trial to treat advanced cutaneous melanoma.